PAREXEL

What PAREXEL does

PAREXEL is a privately held, global biopharmaceutical services company headquartered in Raleigh, North Carolina (since September 2025, relocated from Durham), operating as one of the largest contract research organizations (CROs) with 24,000+ employees across more than 50 countries. The company delivers end-to-end clinical development services spanning portfolio optimization, Phase I-IV clinical trials, regulatory strategy and submissions, market access, real-world evidence, pharmacovigilance, medical affairs and post-approval lifecycle management to large biopharmaceutical companies and emerging biotech sponsors. Backing comes from EQT and Goldman Sachs Asset Management, with the entity legally registered as Parexel International (MA) Corporation.

The company's core technology platform is the proprietary ParexelAI suite, built as the first CRO deployment of Palantir's Artificial Intelligence Platform, integrating natural language processing, machine learning, large language models and generative AI across site selection, medical writing, regulatory documentation, pharmacovigilance and clinical study report generation. Named AI modules include Parexel Reviewer (literature screening), the AI-Enabled Case Processing Optimizer, the Integrated Data Delivery (IDD) ecosystem, and the Vitrana pharmacovigilance platform (acquired May 2026, adding 600 staff). The platform is layered atop partnerships with Weave Bio (regulatory authoring), Paradigm Health (800+ research sites, 2,100+ provider locations), OpenText (cloud content management for 25,000+ users) and integrations with DataWorks (38M diverse US patients) and TriNetX Live (millions of patients in 30+ countries).

PAREXEL generates revenue primarily through quote-based, multi-year enterprise contracts delivered via Full-Service CRO engagements, Functional Service Provider (FSP) outsourcing models, dedicated biotech solutions under the Parexel Biotech sub-brand, and consulting/advisory services (including the Health Advances practice). Its go-to-market is direct enterprise field sales targeting large biopharma and biotech sponsors globally, supplemented by the Site Alliance Network, the Parexel Biotech Incubator (launched June 2026 with Cape Fear BioCapital) and content marketing across an extensive insights library, industry conferences and a podcast series. Headcount is concentrated in India (6,000+, growing toward 8,000), North Carolina (~1,100 at the new Raleigh HQ), and across EMEA and APAC, with the company maintaining 1,300+ regulatory specialists including former regulators from the FDA, EMA, NMPA, MHRA and PMDA.

Name

PAREXEL

Legal name

Parexel International (MA) Corporation

Website

https://parexel.com

Company type

Private

Founded year

1983

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

PAREXEL is a privately held global biopharmaceutical services company (CRO) with 24,000+ employees delivering end-to-end Phase I-IV clinical development, regulatory, market access and pharmacovigilance services to large biopharma and emerging biotech sponsors across 50+ countries, supported by its proprietary ParexelAI suite.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH), Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Medical Writing & Regulatory Submission Support CROs (HLAGAAAG), Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC), Functional Service Providers (FSP) & Resourcing CROs (HLAGAAAM)

Keywords

• Clinical research services
• Biopharmaceutical outsourcing
• Contract research organization
• Regulatory affairs consulting
• Clinical trial management

Headquarters

HQ city

Waltham

HQ country

United States

HQ region

North America

Offices8 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others

Revenue model

1. Full-Service CRO Contracts: Parexel's primary revenue stream — full-service clinical research organization contracts covering Phase I-IV clinical trials, regulatory strategy, market access, real-world evidence, and lifecycle management for biopharmaceutical and biotech sponsors. Engagements are typically multi-year, milestone-based contracts.
2. Functional Service Provider (FSP) Outsourcing: Recurring revenue from dedicated functional resourcing in clinical operations, data management, regulatory affairs, pharmacovigilance, medical affairs, medical writing, and translational medicine. FSP models often involve multi-year contracts with sponsor-dedicated teams.
3. Consulting and Strategic Advisory Services: Strategic consulting including portfolio management, asset valuation, indication prioritization, market access strategy, health economics modeling, and compliance/risk management consulting. Includes the Health Advances partnership for commercial strategy consulting.
4. Patient Safety & Pharmacovigilance Services: Drug safety and pharmacovigilance services covering adverse event monitoring, safety case processing, periodic reports (PSUR/DSUR), and integrated patient safety platforms enhanced by Vitrana technology acquisition creating a single-partner model for PV technology and services.
5. Technology-Enabled Services (ParexelAI): AI-powered services bundled with CRO contracts delivering speed, quality, and efficiency gains. Includes licensing-style access to AI tools and platforms (ParexelAI, Parexel Reviewer, Vitrana PV platform) often combined with human-led services.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels8 records

Core offering

PAREXEL is a global contract research organization (CRO) that delivers full-service clinical development, regulatory, safety/pharmacovigilance, and market access services to biopharmaceutical and biotech sponsors across Phase I-IV trials. The company offers both full-service CRO engagements and Functional Service Provider (FSP) dedicated resourcing models, augmented by its proprietary ParexelAI suite for site selection, medical writing, regulatory documentation, and safety literature review.

Product overview

PAREXEL's offering is a platform-plus-modules architecture of integrated clinical research organization (CRO) services organized around five end-to-end drug development stages - Portfolio Management and Asset Valuation, Early Development and Innovation, Integrated Clinical Development, Approval and Access, and Value Substantiation Lifecycle Management - all unified and accelerated by the proprietary ParexelAI suite (including the Parexel Reviewer NLP literature-screening tool), supported by Operational Excellence (Parexel Precision Pathway, Integrated Data Delivery), FSP Delivery Models (Functional Service Provider), Medical Affairs services (including The Medical Affairs Company / TMAC), Clinical Study Start-up services, a Therapeutic Expertise portfolio (Oncology, Hematology, Neuroscience, Cell & Gene Therapy, Rare Diseases, etc.), and dedicated Biotech solutions under the Parexel Biotech sub-brand (including the new Parexel Biotech Incubator). AI capabilities are layered across modules and powered by partnerships with Palantir, Weave Bio, and Paradigm Health, plus the acquired Vitrana pharmacovigilance platform.

Differentiator

Problem solved

Functional benefit

Brands

• ParexelAI: Proprietary suite of human-led AI services for clinical trials spanning site selection, medical writing, regulatory documentation, and pharmacovigilance.
• Parexel Biotech
• Parexel Biotech Incubator
• The Medical Affairs Company (TMAC)

Products and services

• Portfolio Management and Asset Valuation Drug development portfolio consulting offering including patient insights, portfolio optimization, asset valuation, indication prioritization, early evidence review, and integrated development strategy and planning. Designed for biopharma and biotech sponsors seeking earlier, more informed risk-reward decisions.
• Early Development and Innovation Multi-disciplinary early phase approach integrating Phase I trials, regulatory strategy, biomarker/genomic medicine, real-world evidence, MIDD, market access consulting, clinical logistics, and medical communications to accelerate path to proof of concept.
• Integrated Clinical Development Whole-study solutions for Phase IIb-IV clinical trials including Integrated Data Delivery (IDD), protocol-driven site strategy, regulatory submissions, clinical logistics, drug safety/pharmacovigilance, real-world evidence, and patient inclusion.
• Approval and Access Service line staffed by former regulators and HTA professionals providing tailored global regulatory submissions, compliance/risk management, market access strategy, and health economics modelling for sponsors seeking global market reach.
• Value Substantiation Lifecycle Management Post-approval studies and holistic lifecycle management including real-world evidence, market access, regulatory compliance, and lifecycle optimization with 1,350+ annual product reviews to satisfy regulators and payers.
• FSP Delivery Models Functional Service Provider (FSP) outsourcing providing customized, sponsor-centric clinical development resourcing across clinical operations, data management, medical affairs, medical writing, regulatory, pharmacovigilance, and translational medicine functions with a global talent ecosystem.
• Operational Excellence and Delivery (OED) Office driving continuous improvement in trial delivery through process simplification, technology standardization, cross-functional communication, and change management, including the Parexel Precision Pathway end-to-end operational approach.
• Medical Affairs for Clinical Trials Integrated evidence solutions including RWE, HEOR, market access consultancy, MSL deployment, medical information call center, medical communications, and patient insights/engagement/advocacy across the development lifecycle.
• Clinical Study Start-up Launch Excellence team providing guidance for study start-up combining therapeutic knowledge with site feasibility, project management, process optimization, and risk assessment to compress timelines from protocol finalization to first patient dosed.
• Therapeutic Expertise Services CRO service line covering therapeutic areas including Oncology (80+ ex-agency regulators, ~2,500 sites), Hematology, Neuroscience, General Medicine, Infectious Disease and Vaccines, Immunology, Ophthalmology, Cell and Gene Therapies, Pediatrics, and Rare Diseases.
• Parexel Biotech Dedicated biotech-focused CRO offering tailored services for emerging biotech companies, including regulatory and commercial strategy, trial design and execution, and the Parexel Biotech Incubator for early-stage therapeutics companies.
• The Medical Affairs Company (TMAC) Specialty services subsidiary delivering MSL deployment, medical information call center solutions, medical writing and informatics, and medical meeting coverage. Part of Parexel since 2017 with more than 20 years' experience in medical affairs.
• ParexelAI Proprietary AI-enabled clinical development suite combining Parexel's operational expertise with AI technology across the entire trial lifecycle. Delivers 50% reduction in site selection timelines, 30% reduction in CSR preparation, and 20% reduction in safety literature screening. Built on Palantir's AI Platform.
• Parexel Biotech Incubator Incubator program connecting early-stage therapeutics companies with Parexel's clinical and regulatory expertise at its Raleigh, NC global headquarters. Inaugural partnership with Durham-based seed-stage venture capital firm Cape Fear BioCapital.

Named customers6 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability12 records

Feature8 records

Partnerships

16 partnerships are on record, tiered core, flagship and minor.

• Cape Fear BioCapitalcoreStrategic or Co-development Partner · 22 June 2026Inaugural partnership for the Parexel Biotech Incubator at Raleigh's North Hills Innovation District headquarters, connecting early-stage therapeutics companies with clinical and regulatory expertise. Durham-based seed-stage venture capital firm.
• Palantir TechnologiesflagshipTechnology or Integration · 17 May 2026Parexel was the first CRO to adopt Palantir's Artificial Intelligence Platform, which serves as the enterprise backbone for Parexel's AI-enabled clinical operations, supporting faster, higher-quality study delivery.
• VitranaflagshipStrategic or Co-development Partner · 30 April 2026Acquired AI-enabled end-to-end pharmacovigilance technology platform from Vitrana (Noida-based). Brings 600-person team and intelligent automation platform into Parexel's Patient Safety Services organization. Vitrana will initially operate as 'Vitrana – a Parexel Company'. Enables single-partner model for both PV technology and services.
• AstraZenecacoreStrategic or Co-development Partner · 29 April 2026Phase II TRAVERSE proof-of-concept trial for mantle cell lymphoma under FDA's Real-Time Clinical Trials (RTCT) pilot using Paradigm Health's SPIRE platform for automated real-time data collection and reporting.
• AmgencoreStrategic or Co-development Partner · 29 April 2026Phase Ib STREAM-SCLC proof-of-concept trial for limited-stage small cell lung carcinoma under FDA's RTCT pilot using Paradigm Health's SPIRE platform.
• OpenTextcoreTechnology or Integration · 6 March 2026Parexel migrated its content management system from on-premises deployment to OpenText Cloud, involving approximately 7TB of data and over 25,000 users. The migration enhances GxP regulatory compliance and provides access to AI-powered content management and automation tools.
• Jazz PharmaceuticalscoreStrategic or Co-development Partner · 1 March 2026Co-built a high-performing global data hub in South Africa through joint approaches. Featured as case study in March 2026.
• Neutra Corp / Neutra Life SciencesminorStrategic or Co-development Partner · 20 January 2026Partnership enhancing Neutra's clinical trial capabilities and supporting their pivot into the clinical research industry with projected 1,000%+ year-over-year revenue increase.
• Oracle (E-Business Suite)coreTechnology or Integration · 19 December 2025Parexel experienced a cybersecurity incident involving a zero-day exploit in Oracle E-Business Suite, potentially affecting personal data of an unknown number of individuals. Data breach exposed SSNs and financial information; legal investigations underway.
• Weave BioflagshipStrategic or Co-development Partner · 30 September 2025Parexel serves as Weave Bio's CRO design partner with exclusivity as the only CRO licensed to use Weave's solutions after new product launches. Demonstrated 50% faster completion of IND applications using Weave's AutoIND platform, and 60% faster NDA authoring timelines through regulatory automation. Partnership extends across the full regulatory lifecycle.
• Paradigm HealthflagshipStrategic or Co-development Partner · 14 September 2025Strategic partnership to improve clinical trial design and reduce trial costs through AI-powered solutions and expanded patient access. Together, Parexel and Paradigm provide a network of 800+ research sites and 2,100+ provider locations to transform patient identification and trial access.
• Japanese Cancer Research CentercoreStrategic or Co-development Partner · 3 August 2025Parexel partnered with a Japanese cancer research center (name not specified in source). Strategic alliance to advance oncology clinical development in Japan and Asia-Pacific.
• BayerflagshipStrategic or Co-development Partner · 1 January 2024Longtime CRO partner implementing Bayer's Dynamic Shared Ownership (DSO) operating model through flatter organization structures, decentralized decision-making, and nimble 90-day work cycles focused on mission objectives. Alliance demonstrates significant operational transformation.
• Health AdvancesflagshipStrategic or Co-development PartnerStrategic partnership (acquired/part of Parexel) providing commercial strategy consulting, portfolio optimization, asset valuation, and indication prioritization. Powers Parexel's portfolio management and asset valuation offerings.
• The Medical Affairs Company (TMAC)coreStrategic or Co-development PartnerPart of Parexel since 2017. Delivers MSL deployment, medical information call center solutions, medical writing, informatics, and medical meeting coverage with 20+ years of medical affairs experience.
• MicrosoftcoreTechnology or IntegrationFeatured among Microsoft's 1,000+ customer transformation stories. Uses Azure, Microsoft 365 Copilot, and Azure OpenAI Service. AI investments projected by IDC to yield $22.3 trillion in global economic impact by 2030.

Scale indicators17 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• Labcorp (Drug Development / Covance): Labcorp's Drug Development segment (formerly Covance) is a top-tier global CRO offering full-service clinical development, central lab services, and FSP models. Directly comparable to Parexel across Phase I-IV trials, bioanalytical services, and post-approval lifecycle management. Operates from a parent diagnostics platform that provides structural advantages.
• IQVIA: The largest global CRO and clinical analytics firm, formed from the Quintiles-IMS merger. Directly competes with Parexel across full-service Phase I-IV clinical development, real-world evidence, and technology-enabled services. Operates at significantly larger scale (~80,000+ employees) and is publicly traded, providing both a competitive benchmark and a likely acquirer profile at PE exit.
• Medpace Holdings: Mid-sized, mid-cap publicly-traded CRO focused primarily on Phase II-IV full-service clinical trials for emerging and mid-sized biopharma sponsors. Highly comparable to Parexel's biotech-focused sub-brand; competes on speed, therapeutic expertise, and operational metrics. Notably profitable and has been a share-gainer against larger CROs.
• Syneos Health: Biopharma solutions organization offering full-service CRO and contract commercial services (CCS) to biopharmaceutical customers. Now privately held after Elliott Management take-private in 2023. Direct competitor across clinical development, particularly in commercial and late-stage work, with comparable PE ownership dynamics.
• ICON plc: Major global CRO formed through the PRA Health Sciences combination, now one of the top three full-service CROs worldwide. Directly competes with Parexel in Phase I-IV clinical trials, FSP outsourcing, lab services, and decentralized trial capabilities. Publicly listed with comparable therapeutic depth and AI investment programs.

Broad incumbents

• Thermo Fisher Scientific (PPD): Thermo Fisher acquired PPD in 2021 for $17.4B, integrating it into a much larger life-sciences platform spanning lab supplies, instruments, and clinical services. Competes with Parexel across CRO services but with broader portfolio leverage and significantly greater capital base; less specialized in emerging biotech.
• Charles River Laboratories: Leading preclinical CRO and research models provider with growing clinical and manufacturing services. Overlaps with Parexel in early-phase clinical development and safety assessment, but is more specialized in preclinical and discovery work; broader incumbent across the drug development value chain.

Others

• Veeva Systems: Leading provider of cloud software (Veeva Vault) for life sciences, including clinical, regulatory, quality, and commercial applications. Not a direct CRO competitor but a key technology ecosystem player whose platforms integrate with CROs like Parexel; represents both a partner relationship and a potential disruptor to CRO-built proprietary systems like ParexelAI.

Emerging players

• Worldwide Clinical Trials: Mid-sized global CRO focused on Phase II-IV clinical development across CNS, cardiovascular, metabolic, and rare diseases. Directly comparable to Parexel in therapeutic depth and mid-sized sponsor targeting; smaller scale but a credible specialist alternative for sponsors seeking a more boutique CRO relationship.

Regional players

• WuXi AppTec: China-based global CRO/CDMO offering preclinical, clinical (through WuXi Clinical), and commercial services. Comparable to Parexel across clinical development services but with primary geographic focus on China and APAC; serves many of the same biotech sponsors but with structurally different cost base and geopolitical positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/parexel
• Instagraminstagram.com/parexel
• Xx.com/PAREXEL
• Facebookfacebook.com/Parexel

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries4 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A25 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PAREXEL